Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Blood (2023) 142 (Supplement 1): 4971.

https://doi.org/10.1182/blood-2023-177624

Published: 2023

Journal Articles

Outcomes of Patients with Pre-Existing Invasive Fungal Disease Undergoing Allogeneic Haematopoietic Stem Cell Transplantation — 5 Years Single Centre Experience

Varun Mehra, MRCP, FRCPath, Eleanor Barnwell, Ute Boczek, Stefanie Widya, Kavita Raj, MD PhD, Hugues De Lavallade, Donal McLornan, Victoria Potter, Carmel Rice, FRACP, FRCPA, MBBS, Christina Lim, Michelle Kenyon, Alessandra Bisquera, Judith Marsh, MD, M. Mansour Ceesay, MDFRCP,FRCPath, Antonio Pagliuca, MD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 3216.

https://doi.org/10.1182/blood.V130.Suppl_1.3216.3216

Published: 2017

Journal Articles

Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation

Sangeeta Atwal, MBBS, MRCP, FRCPath, Anjum Bashir Khan, MBChB, MRCP, Victor Noriega, MD, Yogesh Jethava, MB, MRCP, MD, FRCPath, Michelle Kenyon, BSc, RN, Hugues de Lavallade, MD, Donal McLornan, MD, PhD, Victoria T Potter, MBBS, FRCPA, FRACP, Kavita Raj, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 4216.

https://doi.org/10.1182/blood.V120.21.4216.4216

Published: 2012

Journal Articles

Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma

Victor Noriega, MD, Anjum Bashir Khan, MBChB, MRCP, Stephen Devereux, FRCP, FRCPath, PhD, Robert E. Marcus, MBBS, FRCP, FRCPath, Michelle Kenyon, Victoria T Potter, MBBS, FRCPA, FRACP, Ghulam J Mufti, FRCP, FRCPath, M.D., Antonio Pagliuca, MBBS, FRCP, FRCPath, MA

Blood (2012) 120 (21): 2022.

https://doi.org/10.1182/blood.V120.21.2022.2022

Published: 2012

Journal Articles

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Shreyans A Gandhi, MBBS, MD, DNB, MRCP, Victoria T Potter, BSc, MBBS, Victoria J. Tindell, MBChB, Rachel Kesse-Adu, MBBS, Laura Reiff-Zall, Michelle Kenyon, Judith C. W. Marsh, MD, Aloysius Y Ho, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, ZiYi Lim, MD

Blood (2010) 116 (21): 1304.

https://doi.org/10.1182/blood.V116.21.1304.1304

Published: 2010

Journal Articles

Late Relapses Following Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation for Myeloid Malignancies Can Be Effectively Salvaged with Intensive Chemotherapy Followed by Cellular Therapy.

Austin Gladston Kulasekararaj, MBBS, MD, MRCP, FRCP, Ziyi Lim, Pramila Krishnamurthy, M. Mansour Ceesay, MRCP, FRCPath, Michelle Kenyon, BSc, RN, Janet Hayden, Judith C W Marsh, Aloysius YL Ho, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 2265.

https://doi.org/10.1182/blood.V114.22.2265.2265

Published: 2009

Journal Articles

A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab.

Aloysius YL Ho, MBBS, FRCP, FRCPath, Pramila Krishnamurthy, ZiYi Lim, MD, Michelle Kenyon, BSc, RN, Aleksander Mijovic, FRCPath, Stephen Devereux, FRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 2266.

https://doi.org/10.1182/blood.V114.22.2266.2266

Published: 2009

Journal Articles

Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion.

ZiYi Lim, MD, Sarah Bennett, Aloysius YL Ho, MBBS, FRCP, FRCPath, Austin G Kulasekararaj, Sunil Gupta, MBBS, MRCP, Michelle Kenyon, BSc, RN, Janet Hayden, Judith C W Marsh, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2009) 114 (22): 3362.

https://doi.org/10.1182/blood.V114.22.3362.3362

Published: 2009

Journal Articles

Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease.

ZiYi Lim, Murugaiyan Thanigaikumar, Shreyans Gandhi, Laurence Pearce, Michelle Kenyon, Aloysius Y.L. Ho, Stephen Devereux, Antonio Pagliuca, Ghulam J. Mufti

Blood (2007) 110 (11): 1994.

https://doi.org/10.1182/blood.V110.11.1994.1994

Published: 2007

Journal Articles

Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.

M. Mansour Ceesay, MRCPath, ZiYi Lim, MRCPath, Michelle Kenyon, Aloysius Y.L. Ho, FRCPath, Stephen Devereux, FRCPath, Steve Schey, FRCPath, Aleksandar Mijovic, FRCPath, Antonio Pagliuca, FRCPath, Ghulam J. Mufti, FRCPath

Blood (2007) 110 (11): 1665.

https://doi.org/10.1182/blood.V110.11.1665.1665

Published: 2007

Journal Articles

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Wendy Ingram, MD, Zi Y. Lim, MD, Michelle Kenyon, RN, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Mufti Ghulam, MD

Blood (2006) 108 (11): 3108.

https://doi.org/10.1182/blood.V108.11.3108.3108

Published: 2006

Journal Articles

Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes.

ZiYi Lim, Aloysius Ho, Michelle Kenyon, Stephen Devereux, Rafael Duarte, Antonio Pagliuca, Ghulam Mufti

Blood (2005) 106 (11): 444.

https://doi.org/10.1182/blood.V106.11.444.444

Published: 2005

Journal Articles

Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT).

ZiYi Lim, Dragana Milojkovic, Laurence Pearce, Michelle Kenyon, Aloysius Ho, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti

Blood (2005) 106 (11): 1762.

https://doi.org/10.1182/blood.V106.11.1762.1762

Published: 2005

Journal Articles

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

Aloysius Y. L. Ho, Antonio Pagliuca, Michelle Kenyon, Jane E. Parker, Aleksandar Mijovic, Stephen Devereux, Ghulam J. Mufti

Blood (2004) 104 (6): 1616–1623.

https://doi.org/10.1182/blood-2003-12-4207

Published: 2004

Journal Articles

Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200

Aloysius Y. L. Ho, Michelle Kenyon, Ihab El-Hemaidi, Stephen Devereux, Antonio Pagliuca, Ghulam J. Mufti

Blood (2003) 101 (2): 779–780.

https://doi.org/10.1182/blood-2002-07-2256

Published: 2003

NARROW

Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre Experience

Outcomes of Patients with Pre-Existing Invasive Fungal Disease Undergoing Allogeneic Haematopoietic Stem Cell Transplantation — 5 Years Single Centre Experience

Demethylating Agents As a Salvage Treatment in Relapsed Myeloid Diseases Following Allogeneic Bone Marrow Transplantation

Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma

Alemtuzumab-Based RIC HSCT with Pre-Emptive DLI as An Effective Strategy to Achieve Long-Term Disease Remission In Patients with High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Late Relapses Following Reduced Intensity Conditioning Allogeneic Haematopoietic Stem Cell Transplantation for Myeloid Malignancies Can Be Effectively Salvaged with Intensive Chemotherapy Followed by Cellular Therapy.

A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab.

Comparative Analysis of Sibling Donor Reduced Intensity Conditioning Regimen for High Risk AML/MDS Using Anti-Thymocyte Globulin Versus Alemtuzumab for T-Cell Depletion.

Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease.

Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Reduced Intensity Conditioned Volunteer Unrelated Donor Transplants Using Alemtuzumab Are Safe and Effective in Older Patients with Myelodysplastic Syndromes.

Matched Pair Analysis of Intravenous vs Oral Busulphan as Part of Fludarabine-Busulphan-Campath (Alemtuzumab) Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT).

Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only